Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 6, 2026, 2:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,136 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Combinations Clear all
Completed Phase 1Phase 2 Interventional Results available

An Investigational Study of Immunotherapy Combinations in Participants With Solid Cancers That Are Advanced or Have Spread

NCT03459222
View directory record Official record
Conditions
Advanced Cancer
Interventions
Relatlimab, Nivolumab, BMS-986205, Ipilimumab
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
5
States / cities
Duarte, California • Aurora, Colorado • Baltimore, Maryland + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 5, 2026 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Effects of Gabapentin Versus Placebo on Buprenorphine Detoxification of Opioid-dependent Individuals

NCT01262092
View directory record Official record
Conditions
Opioid Dependence, Opioid Withdrawal, Opioid Detoxification
Interventions
Buprenorphine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2013 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Clinical Trial of CAM2038, Long-acting Subcutaneous Buprenorphine Injections for Treatment of Patients With Opioid Dependence

NCT02651584
View directory record Official record
Conditions
Opioid Use Disorders
Interventions
CAM2038 SC injection, SL BPN/NX tabs, placebo SC injections, SL placebo tablets
Drug
Lead sponsor
Braeburn Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
36
States / cities
Birmingham, Alabama • Haleyville, Alabama • Hamilton, Alabama + 32 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2019 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety and Immunogenicity of HIV Clade C DNA Vaccine and MF59- or AS01B-Adjuvanted Clade C Env Protein Vaccines in Various Combinations in Healthy, HIV-Uninfected Adults

NCT02915016
View directory record Official record
Conditions
HIV Infections
Interventions
DNA-HIV-PT123 vaccine, Bivalent Subtype C gp120/MF59 vaccine, Bivalent Subtype C gp120/AS01B vaccine, Placebo
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 40 Years
Enrollment
334 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
8
States / cities
Birmingham, Alabama • Boston, Massachusetts • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2022 · Synced Sep 6, 2026, 2:58 PM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

Or v IV Antibiotics for Infection

NCT04723940
View directory record Official record
Conditions
Joint Infection
Interventions
Bactrim, Cefadroxil, Doxycycline Hcl, Clindamycin
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
308 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 25, 2021 · Synced Sep 6, 2026, 2:58 PM EDT
Active, not recruiting Phase 3 Interventional

Open-label Study to Assess Reduction of Background Asthma Medication While Sustaining Asthma Control and Clinical Remission With Tezepelumab in Patients 12-80yrs With Severe Asthma.

NCT06473779
View directory record Official record
Conditions
Severe Asthma
Interventions
Tezepelumab, Budesonide/formoterol, Albuterol/budesonide (AIRSUPRA®), Mannitol, Salbutamol
Combination Product
Lead sponsor
AstraZeneca
Industry
Eligibility
12 Years to 80 Years
Enrollment
326 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
8
States / cities
Palmdale, California • Colorado Springs, Colorado • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Results available

Attenuation of the Side Effect Profile of Regadenoson: Study With Aminophylline in Patients With Severe Kidney Disease Undergoing Myocardial Perfusion Imaging

NCT01336140
View directory record Official record
Conditions
Patients With Severe Chronic Kidney Disease Being Evaluated With Nuclear Stress Testing of the Heart Using the Stress Agent Regadenoson
Interventions
Aminophylline, Placebo
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 25, 2023 · Synced Sep 6, 2026, 2:58 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

Regulating Homeostatic Plasticity and the Physiological Response to rTMS

NCT03309696
View directory record Official record
Conditions
Tinnitus
Interventions
sham tDCS and sham rTMS, sham tDCS and active rTMS, active tDCS and active rTMS
Device
Lead sponsor
University of Arkansas
Other
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Sep 6, 2026, 2:58 PM EDT
Active, not recruiting Phase 2 Interventional

A Platform Study of Novel Immunotherapy Combinations as First-Line Treatment in Participants With PD-L1 Positive Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck- GALAXIES H&N-202

NCT06062420
View directory record Official record
Conditions
Neoplasms, Head and Neck
Interventions
Dostarlimab, Belrestotug, Nelistotug, Remzistotug
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
316 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
5
States / cities
New Haven, Connecticut • Iowa City, Iowa • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2026 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Early Phase 1 Interventional

New Technology to Assess Treatment for Chronic Obstructive Pulmonary Disease (COPD)

NCT02826343
View directory record Official record
Conditions
Pulmonary Disease, Chronic Obstructive
Interventions
Xenon129 MRI imaging, Gadolinium MRI, Advair (250mcg/50mcg) one puff twice a day
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 3, 2020 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Laboratory Study of Cannabidiol on the Effects of Smoked Marijuana

NCT01844687
View directory record Official record
Conditions
Smoking, Marijuana
Interventions
CBD
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
18 Years to 50 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Lexington, Kentucky • New York, New York • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 6, 2026, 2:58 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Nexplanon Removal: Subcutaneous vs. Topical Lidocaine

NCT04467125
View directory record Official record
Conditions
Contraception
Interventions
Eutectic Lidocaine Prilocaine, Subcutaneous Lidocaine
Drug
Lead sponsor
Augusta University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 9, 2020 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Results available

Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections

NCT00690378
View directory record Official record
Conditions
Complicated Urinary Tract Infection
Interventions
NXL104/ceftazidime, Imipenem/Cilastatin
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
42
States / cities
Birmingham, Alabama • Dothan, Alabama • Mobile, Alabama + 38 more
Source: ClinicalTrials.gov public record
Updated May 24, 2018 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Phase 3 Interventional

Next Generation Ingestible Sensors for Medication Adherence Measurement

NCT05592613
View directory record Official record
Conditions
HIV Infection, Adherence, Medication, Adherence, Treatment, Pre-Exposure Prophylaxis, Antiretroviral Therapy
Interventions
Next-generation Reader and ID-Cap System, Truvada for pre-exposure prophylaxis (PrEP), Biktarvy for antiretroviral therapy (ART)
Device · Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 24, 2024 · Synced Sep 6, 2026, 2:58 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional Results available

A Study to Assess the Safety and Efficacy of Two Combinations of Isocitrate Dehydrogenase (IDH) Mutant Targeted Therapies Plus Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) Harboring IDH Mutations Who Are Not Candidates to Receive Intensive Induction Chemotherapy

NCT02677922
View directory record Official record
Conditions
Leukemia, Myeloid, Acute
Interventions
AG-120, Azacitidine, AG-221
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
9
States / cities
Duarte, California • New Haven, Connecticut • Chicago, Illinois + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2026 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children

NCT02991937
View directory record Official record
Conditions
Appendicitis
Interventions
Piperacillin/Tazobactam, Surgical Treatment
Drug · Procedure
Lead sponsor
NYU Langone Health
Other
Eligibility
6 Years to 17 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 20, 2022 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Results available

Acute Otitis Media (AOM) Therapy Trial in Young Children

NCT00377260
View directory record Official record
Conditions
Acute Otitis Media
Interventions
amoxicillin-clavulanate, Placebo
Drug
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Months to 23 Months
Enrollment
291 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 4, 2016 · Synced Sep 6, 2026, 2:58 PM EDT
Completed No phase listed Observational Results available

Mental Imagery Therapy for Autism (MITA) - an Early Intervention Computerized Language Training Program for Children With ASD

NCT02708290
View directory record Official record
Conditions
Autistic Disorder, Autism, ASD
Interventions
MITA Prefrontal Synthesis exercises - each activity adapts to deliver the exercise that is at the exact level of difficulty appropriate for a child at any given point in time
Other
Lead sponsor
ImagiRation, LLC
Industry
Eligibility
2 Years to 12 Years
Enrollment
6,454 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 26, 2020 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Study to Assess the Safety, Tolerability and Pharmacokinetics of Fimepinostat (CUDC-907) in Patients With Lymphoma

NCT01742988
View directory record Official record
Conditions
Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Relapsed and/or Refractory Lymphoma, Relapsed Ddiffuse Large B-Cell Lymphoma (DLBCL), Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Relapsed and/or Refractory Diffuse Large B-Cell Lymphoma (DLBCL), Double-hit Lymphoma (DHL), Triple-hit Lymphoma (THL), Double-expressor Lymphoma (DEL), High-grade B-cell Lymphoma (HGBL)
Interventions
fimepinostat, Rituximab, venetoclax
Drug
Lead sponsor
Curis, Inc.
Industry
Eligibility
18 Years and older
Enrollment
106 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
11
States / cities
Los Angeles, California • Sarasota, Florida • Atlanta, Georgia + 8 more
Source: ClinicalTrials.gov public record
Updated May 5, 2021 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Safety and Efficacy of Stribild Versus Atripla in Human Immunodeficiency Virus, Type 1 (HIV-1) Infected, Antiretroviral Treatment-Naive Adults

NCT01095796
View directory record Official record
Conditions
HIV, HIV Infections
Interventions
Stribild, Atripla, Stribild Placebo, Atripla Placebo
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
707 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
97
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2015 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Phase 1 Interventional

Temodar Plus Tyrosine Kinase Inhibitors for Progressive CNS Disease

NCT04541407
View directory record Official record
Conditions
Non Small Cell Lung Cancer, CNS Progression
Interventions
Temozolomide plus Osimertinib, Temozolomide plus Lorlatinib
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Dose-ranging Study

NCT01712451
View directory record Official record
Conditions
Abdominal Contour Defects
Interventions
salmeterol xinafoate, fluticasone propionate, Placebo, salmeterol xinafoate
Drug
Lead sponsor
Neothetics, Inc
Industry
Eligibility
18 Years to 45 Years
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
6
States / cities
Beverly Hills, California • San Diego, California • New York, New York + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 25, 2015 · Synced Sep 6, 2026, 2:58 PM EDT
Completed Phase 4 Interventional Results available

An Evaluation of the Fixed Combination Brimonidine Tartrate 0.2%/ Timolol Maleate 0.5% to Latanoprost 0.005% in Glaucoma or Ocular Hypertension Subjects

NCT00811564
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
fixed combination of brimonidine tartrate 0.2% timolol maleate 0.5% ophthalmic solution, latanoprost 0.005%
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Slingerlands, New York
Source: ClinicalTrials.gov public record
Updated Sep 20, 2011 · Synced Sep 6, 2026, 2:58 PM EDT
Terminated Not applicable Interventional Results available

Dipyridamole Assessment for Flare Reduction in Systemic Lupus Erythematosus (SLE)

NCT01781611
View directory record Official record
Conditions
Systemic Lupus Erythematosus
Interventions
extended release dipyridamole 200mg/aspirin 25mg, 81mg aspirin
Drug
Lead sponsor
Oklahoma Medical Research Foundation
Other
Eligibility
18 Years to 70 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Nov 24, 2020 · Synced Sep 6, 2026, 2:58 PM EDT